Vaccine Response
14
3
4
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
36%
5 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults
Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination
Systems Biological Assessment of Statin Effect on Vaccine Responses
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
Durability of Vaccine Responses
PREPARE-iVAC Trial
Melatonin and Vaccine Response, Immunity, and Chronobiology Study
Probiotics and Influenza Vaccination Response
Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia
SafeTy and Efficacy of Preventative CoVID Vaccines
Effectiveness of mRNA Covid-19 Vaccines on Cancer Patients:Observational Study. (ANTICOV)
Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year
Iron and Prebiotics Fortification in Kenyan Infants
Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers